title: Therapeutic intervention in dementia.
abstract: The search for novel therapeutics for human cognitive disorders has intensified. Neurotransmitter replacement therapies represent a short-term hope for treating cognitive dysfunction associated with Alzheimer's disease (AD). AD, however, is clearly a neurodegenerative disease and is characterized by a loss of synaptic elements. Ultimately, synaptic loss must be halted to alter the disease course. Agents mimicking or modulating the actions of neurotrophic factors may be useful. They may restore lost function and exert anabolic effects on existing neurons, making treated cells less susceptible to neurotoxic insult (i.e., excitotoxicity, oxidative stress, etc.). Intervening in the biogenesis of amyloid plaques and blunting local inflammatory responses may provide the ultimate treatment for AD. The success of any treatment, however, rests on early diagnosis. Early intervention in the neurodegenerative disease process will be required. Without early intervention, the risk of maintaining patients in a premorbid state is high. Therefore, it is likely that no single approach will provide optimal therapy for the AD patient and multifactorial treatment strategies may be required.
authors.affiliation: Parke-Davis Pharmaceutical Research, Warner-Lambert Co., Ann Arbor, MI 48106-1047.
authors.forename: R E
authors.initials: RE
authors.lastname: Davis
authors.forename: M R
authors.initials: MR
authors.lastname: Emmerling
authors.forename: J C
authors.initials: JC
authors.lastname: Jaen
authors.forename: W H
authors.initials: WH
authors.lastname: Moos
authors.forename: K
authors.initials: K
authors.lastname: Spiegel
mesh_terms: D000544:Alzheimer Disease / Q000175:diagnosis / Q000209:etiology; D000818:Animals; D003072:Cognition Disorders / Q000188:drug therapy; D003704:Dementia / Q000188:drug therapy*; D004195:Disease Models, Animal; D006801:Humans; D018377:Neurotransmitter Agents / Q000627:therapeutic use
chemical_list: D018377:Neurotransmitter Agents